Compare Crispr Therapeutics AG (CRSP) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Schwab US Dividend Equity ETF — how do they compare? Crispr Therapeutics AG trades at $51.2 (market cap $4.88B), while Schwab US Dividend Equity ETF trades at $33.09 (market cap $110.56B). The key difference: Schwab US Dividend Equity ETF is far larger — about 22.7× Crispr Therapeutics AG's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| CRSP | SCHD | |
|---|---|---|
Market Cap | $4.88B | $110.56B |
Volume | 2,861,747 | 23,539,168 |
Sector | Health | Broad Market / Factor |
52-Week High | $74.92 | $35.21 |
52-Week Low | $44.34 | $26.44 |
Typical Hold Time | 77 Days | 62 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
SCHD trades at $32.65, down 0.61% with a bearish technical signal from moving averages. Recent news highlights its strong 2026 performance against the S&P 500 and a recent dividend declaration. The ETF's defensive dividend strategy faces pressure from rising interest rates, contributing to recent price weakness from August highs near $35.
The outlook balances income growth potential against interest rate sensitivity. Near-term support at $32 provides a key level to watch, while the dividend-focused approach offers stability for long-term investors despite current technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
